DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Indoco Remedies Limited — Updates

NSE 1d ago·5 Sept 2026, 8:07 am

Indoco Remedies

Indoco Remedies has informed exchanges that the USFDA conducted an inspection at its sterile manufacturing facility in Goa. This inspection is a routine regulatory activity to evaluate the company's adherence to Good Manufacturing Practices (GMP). The outcome of this inspection will be communicated to the market once it is officially received.

For investors, this news is neutral to positive. A successful inspection typically signals strong quality control and operational compliance, which can support the company's ability to export products to the US. Conversely, a warning letter would raise concerns about regulatory hurdles. The stock's reaction will depend on the final inspection report.